atezolizumab,tiragolumab,carboplatin,etoposide
roche
['atezo', 'improve ', 'tiragolumab', 'sclc']
#asco22 overall, the addition of the anti #tigit antibody tiragolumab to the impower 133 regimen of carboplatin, etoposide, and atezolizumab did not improve pfs or os in #sclc. tigit not likely to be a meaningful target in unselected sclc. await results from other cancer types. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him